Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data

Continuing tyrosine kinase inhibitor (TKI)-mediated targeting of the BCR-ABL1 oncoprotein is the standard therapy for chronic myeloid leukemia (CML) and allows for a sustained disease control in the majority of patients. While therapy cessation for patients appeared as a safe option for about half o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fassoni, Artur C., Baldow, Christoph, Roeder, Ingo, Glauche, Ingmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278983/
https://www.ncbi.nlm.nih.gov/pubmed/29954936
http://dx.doi.org/10.3324/haematol.2018.194522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278983/
https://www.ncbi.nlm.nih.gov/pubmed/29954936
http://dx.doi.org/10.3324/haematol.2018.194522

Ejemplares similares